FOI 9583 – Q4

Q4. How many patients were treated **by department** in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Respiratory departments	Dermatology departments	Other departments
4.1 Benralizumab (Fasenra)	0	0	0
4.2 Depemokimab (Exdensur)	0	0	0
4.3 Dupilumab (Dupixent)	0	37	0
4.4 Mepolizumab (Nucala)	0	0	0
4.5 Omalizumab (Xolair)	<=5	7	<=5
4.6 Reslizumab (Cinqaero)	0	0	0
4.7 Tezepelumab (Tezspire)	0	0	0